| Literature DB >> 26434953 |
Gen Zhang1, Li-Sheng He2, Yue Him Wong1, Ying Xu3, Yu Zhang3, Pei-Yuan Qian1.
Abstract
The MKK3-p38 MAPK pathway has been reported to mediate larval settlement in Amphibalanus (=Balanus) amphitrite. To clarify the underlying molecular mechanism, we applied label-free proteomics to analyze changes in the proteome of cyprids treated with a p38 MAPK inhibitor. The results showed that the expression levels of 80 proteins were significantly modified (p < 0.05). These differentially expressed proteins were assigned to 15 functional groups according to the KOG database and 9 pathways were significantly enriched. Further analysis revealed that p38 MAPK might regulate the energy supply and metamorphosis. Two potential regulatory proteins, CUB-serine protease and PKAα, were both down-regulated in expression. CUB-serine protease localized to postaxial seta 2 and 3, as well as the 4 subterminal sensilla in the antennule. Importantly, it was co-localized with the neuron transmitter serotonin in the sections, suggesting that the CUB-serine protease was present in the neural system. PKAα was highly expressed during the cyprid and juvenile stages, and it was co-localized with phospho-p38 MAPK (pp38 MAPK) to the cement gland, suggesting that PKAα might have some functions in cement glands. Overall, p38 MAPK might regulate multiple functions in A. amphitrite cyprids, including the energy supply, metamorphosis, neural system and cement glands.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26434953 PMCID: PMC4593178 DOI: 10.1038/srep14767
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1An overview of significantly differentially expressed proteins.
(A) A volcano plot showing the distribution of fold change and p-value of all proteins. The vertical axis indicates –log10(p-value) and the horizontal axis indicates log2(fold change). The red rectangles include proteins with the fold change higher than 1.2 or lower than 0.83 with p < 0.05. Dots out of the range of ±7 at the horizontal axis were plotted at the line of ±7. (B) Functional grouping of proteins that were significantly changed in response to SB203580 treatment.
Total spectral counts of proteins involved in different KOG functional groups.
| No. | Functional group | Number of proteins | Total spectral counts | p value | |
|---|---|---|---|---|---|
| Control | SB203580 | ||||
| 1 | Function unknown | 18 | 562.0 ± 25.7 | 416.7 ± 16.3 | 0.002 |
| 2 | Energy production and conversion | 9 | 240.0 ± 8.8 | 326.7 ± 19.3 | 0.004 |
| 3 | Amino acid transport and metabolism | 10 | 218.7 ± 9.0 | 107.3 ± 15.8 | 0.001 |
| 4 | Carbohydrate transport and metabolism | 5 | 120.0 ± 5.7 | 79.3 ± 9.6 | 0.006 |
| 5 | Extracellular structures | 8 | 116.0 ± 12.3 | 128.0 ± 0.0 | 0.150 |
| 6 | Secondary metabolites biosynthesis, transport and catabolism | 3 | 114.7 ± 4.5 | 76.7 ± 5.4 | 0.001 |
| 7 | Posttranslational modification, protein turnover, chaperones | 9 | 114.7 ± 12.8 | 156.0 ± 8.5 | 0.015 |
| 8 | Translation, ribosomal structure and biogenesis | 5 | 108.7 ± 2.9 | 115.3 ± 5.4 | 0.126 |
| 9 | Cytoskeleton | 4 | 53.3 ± 2.9 | 26.7 ± 2.2 | 0.000 |
| 10 | Cell cycle control, cell division, chromosome partitioning | 2 | 27.3 ± 2.9 | 14.7 ± 0.8 | 0.004 |
| 11 | Lipid transport and metabolism | 2 | 18.0 ± 1.4 | 34.7 ± 2.9 | 0.002 |
| 12 | Cell motility | 1 | 15.3 ± 1.6 | 4.0 ± 2.4 | 0.005 |
| 13 | Signal transduction mechanisms | 1 | 14.7 ± 0.8 | 10.0 ± 1.4 | 0.012 |
| 14 | Cell wall/membrane/envelope biogenesis | 2 | 8.0 ± 2.4 | 7.3 ± 1.6 | 0.398 |
| 15 | Nucleotide transport and metabolism | 1 | 6.7 ± 2.2 | 0.7 ± 0.8 | 0.017 |
The spectral counts among three biological replicates are represented as the mean ± SE.
*indicates significant difference between SB203580 treatment and control (p < 0.05).
Enriched pathways of significantly changed proteins in response to SB203580 treatment.
| ID | Pathway name | Input number | Background number | Corrected | Contig input | |
|---|---|---|---|---|---|---|
| hsa01100 | Metabolic pathways | 25 | 1213 | 0.0000 | 0.0003 | CL17009.Contig1, CL11184.Contig1, CL4572.Contig1, Unigene11462, Unigene11511, CL14828.Contig1, CL15192.Contig1, Unigene10435, CL6274.Contig1, CL7745.Contig1, CL1569.Contig1, CL11285.Contig1, CL992.Contig1, CL7151.Contig1, CL4041.Contig1, CL1.Contig245, CL791.Contig1, CL16496.Contig1, Unigene30671, CL8680.Contig1, CL593.Contig2, CL4543.Contig1, CL4124.Contig1, CL593.Contig1, CL6901.Contig1 |
| hsa00280 | Valine, leucine and isoleucine degradation | 5 | 44 | 0.0000 | 0.0012 | CL6901.Contig1, CL4572.Contig1, Unigene11462, CL11285.Contig1, CL17009.Contig1 |
| hsa00190 | Oxidative phosphorylation | 6 | 133 | 0.0005 | 0.0098 | CL14828.Contig1, CL593.Contig2, CL791.Contig1, CL1569.Contig1, CL593.Contig1, Unigene11511 |
| hsa00480 | Glutathione metabolism | 4 | 49 | 0.0006 | 0.0105 | CL2356.Contig1, CL1199.Contig2, CL16496.Contig1, CL4955.Contig1 |
| hsa01200 | Carbon metabolism | 5 | 106 | 0.0013 | 0.0194 | CL6901.Contig1, CL4572.Contig1, Unigene11462, CL11285.Contig1, CL17009.Contig1 |
| hsa00640 | Propanoate metabolism | 3 | 28 | 0.0014 | 0.0204 | CL4572.Contig1, CL11285.Contig1, CL17009.Contig1 |
| hsa00830 | Retinol metabolism | 4 | 64 | 0.0015 | 0.0211 | CL7745.Contig1, CL304.Contig5, CL304.Contig4, CL4124.Contig1 |
| hsa00591 | Linoleic acid metabolism | 3 | 29 | 0.0016 | 0.0214 | CL7151.Contig1, CL15192.Contig1, CL4124.Contig1 |
| hsa04610 | Complement and coagulation cascades | 4 | 69 | 0.0020 | 0.0246 | CL1088.Contig2, CL7.Contig9, CL15271.Contig1, CL6481.Contig1 |
The pathway enrichment was assessed using KEGG pathway analysis. The background number indicates the number of proteins included in the pathway in KEGG database. The input number means the number of proteins found in this study matching with the pathway.
Figure 2Characterization of the amino acid sequence of CUB-serine protease.
(A) Amino acid sequence alignment of the CUB-serine protease from Amphibalanus amphitrite, Haemaphysalis longicornis (BAD21298.1) and Panulirus argus (AF357226.1). The cleavage site (Ile) is labeled with a green asterisk. The three active sites (His, Asp and Ser) and three substrate-binding sites (Asp, Ser and Gly) in the serine protease domain are marked with red pound signs and blue arrows, respectively. The predicted signal peptides are boxed with a red line. (B) Motif analysis of CUB-serine protease. CUB: complement C1r/C1s, Uegf, Bmp1 domain; Tryp_SPc: Trypsin-like serine protease domain; LDLa: low-density lipoprotein receptor domain class A.
Figure 3Characterization of CUB-Serine protease expression.
(A) Two bands corresponding to 58 and 33 kDa were detected using an antibody against the CUB domain. Two bands corresponding to 58 and 25 kDa were detected using an antibody against the serine protease domain. Ab(N): antibody raised against the N-terminus of the CUB-serine protease (CUB domain). Ab(C): antibody raised against the C-terminus of the CUB-serine protease (serine protease domain). (B) Western blot showing that the CUB-serine protease was highly expressed in nauplius VI and the cyprid stages. Three bands, including the intact protein, CUB domain and serine protease domain of the CUB-serine protease, were visualized. The signals of the isolated CUB and serine protease domains were much stronger than that of the intact protein. Nau: nauplius. (C) Western blot showing that 5, 10 and 20 μM of SB203580 decreased the level of the intact protein as well as the isolated CUB and serine protease domains of the CUB-serine protease.
Figure 4Immunostaining of whole mount cyprids revealed that the CUB-serine protease was localized to postaxial seta 2 and 3 as well as the four subterminal sensilla.
(A) Schematic representation of a cyprid antennule. AD: attachment disc; AS2-4: antennulary segments 2–4; STS1-4: subterminal sensilla 1–4; TS-A, B, D and E: terminal sensilla A, B, D and E; PS2 and 3: postaxial seta 2 and 3. (B) Localization of the CUB-serine protein using antibodies against the CUB and the serine protease domains. The fluorescent signals from a set of Z-stack images were combined. The results showed that the CUB-serine protease localized to PS2, PS3 and four STS, which are indicated by yellow arrows.
Figure 5Immunostaining of the CUB-serine protease in cyprid sections.
For each target protein, a transverse section and a longitudinal section are shown. (A) Immunostaining of CUB-serine protease showed signals at circumesophageal connectives in the cross sections, and at the nerve fibers nearby body wall in the transverse sections (Black arrows). (B) Control. Samples were incubated directly with the secondary antibody without any primary antibodies. No obvious singles were observed. TA: thoracic appendage; CC: circumesophageal connective; CG: cement gland; OC: oil cell; CE: compound eye.
Figure 6Characterization of PKAα expression.
(A) Western blot showing that the level of PKAα decreased in response to 10 and 20 μM SB203580. (B) PKAα was highly expressed during the cyprid and juvenile stages.
Figure 7Immunostaining results against PKAα and pp38.
Both PKAα and pp38 were localized to the collective duct of cement gland. CG: cement gland; CE: compound eye.